As of my last update in October 2023, there is no widely recognized chemical substance known as "RX-37" with the CAS number "1627715-60-9." It is possible that this compound is a novel or proprietary substance that has not been extensively documented in publicly available scientific literature or databases. In general, chemical substances are characterized by their molecular structure, physical properties (such as melting point, boiling point, and solubility), chemical reactivity, and potential applications. If RX-37 is a newly developed compound, its characteristics would typically be determined through experimental studies, including spectroscopic analysis, chromatography, and other analytical techniques. For accurate and detailed information, it is advisable to consult specialized databases, scientific publications, or proprietary sources that may provide insights into its properties and potential uses.

RX-37 is a potent BET inhibitor. RX-37  binds to BET bromodomain proteins (BRD2, BRD3, and BRD4) with Ki values of 3.2-24.7 nM and demonstrates high selectivity over other non-BET bromodomain-containing proteins. RX-37 potently and selectively inhibits cell growth in human acute leukemia cell lines harboring the rearranged mixed lineage leukemia 1 gene. RX-37 represents a promising lead compound for the development of a new class of therapeutics for the treatment of human cancer and other conditions.

RX-37

1627715-60-9: As of my last update in October 2023, there is no widely recognized chemical substance known as "RX-37" with the CAS number "1627715-60-9." It is possible that this compound is a novel or proprietary substance that has not been extensively documented in publicly available scientific literature or databases. In general, chemical substances are characterized by their molecular structure, physical properties (such as melting point, boiling point, and solubility), chemical reactivity, and potential applications. If RX-37 is a newly developed compound, its characteristics would typically be determined through experimental studies, including spectroscopic analysis, chromatography, and other analytical techniques. For accurate and detailed information, it is advisable to consult specialized databases, scientific publications, or proprietary sources that may provide insights into its properties and potential uses.

RX-37, a potent BET inhibitor (Ki: 3.2-24.7 nM for BRD2/3/4), selectively hinders growth in leukemia cells with MLL1 gene rearrangement.

CAS 1627715-60-9

RX-37

RX-37

Ref: TM-T28630